Abstract: Methods and formulations for providing efficacious pain relief by transdermal delivery of cannabidiol (CBD), the formulations having a high weight ratio of CBD to (?)-trans-?9-tetrahydrocannabinol (THC).

Abstract: There are disclosed topical silver(II) antibiotic formulations. Other embodiments are also disclosed.

Abstract: Topical formulations for application to exposed body tissue.

Abstract: There are disclosed topical silver(II) antibiotic formulations. Other embodiments are also disclosed.

Abstract: Topical formulations for application to exposed body tissue.

Abstract: There are disclosed topical silver(II) antibiotic formulations. Other embodiments are also disclosed.

Abstract: There are disclosed topical silver(II) antibiotic formulations. Other embodiments are also disclosed.

Abstract: There are disclosed topical silver(II) antibiotic formulations. Other embodiments are also disclosed.

Abstract: Topical formulations for application to exposed body tissue.

Abstract: A formulation including at least one silver oxide including a silver(II) oxide, the silver(II) oxide having an irregular macrocrystal structure, the silver oxide having an average particle size (D50) below 8 micrometers, the irregular macrocrystal structure characterized by a diffraction peak in a {111} diffraction plane having at least one of the following structural properties: (i) a measured full width half maximum (FWHM) of the peak being at least 0.24 degrees of 2?; and (ii) a net full width half maximum (net FWHM) of the peak being at least 0.14 degrees of 2?.

Abstract: Topical formulations for application to exposed body tissue.

Abstract: There are disclosed topical silver(II) antibiotic formulations. Other embodiments are also disclosed.

Abstract: Topical formulations for application to exposed body tissue.

Abstract: A topical formulation for application to exposed body tissue, the formulation comprising a silver(II) oxide and zinc oxide, intimately dispersed within a carrier medium.

Abstract: A topical formulation for application to exposed body tissue, the formulation containing: (a) a silver oxide, and (b) at least one inorganic whitener; selected from the group of inorganic whiteners consisting of an inorganic magnesium compound and an inorganic calcium compound, said silver oxide and said inorganic whitener compound intimately dispersed within a carrier medium, and wherein a ratio of said inorganic whitener compound, to said silver oxide, is at least 0.2:1, by weight.

Abstract: A biocompatible antibiotic formulation suitable for application to skin tissue, the formulation including: (a) a silver(II) oxide; (b) a hydrophilic clay; and (c) a base, said silver(II) oxide and said hydrophilic clay being intimately dispersed within a base.

Abstract: A formulation including at least one silver oxide including a silver(II) oxide, the silver(II) oxide having an irregular macrocrystal structure, the silver oxide having an average particle size (D50) below 8 micrometers, the irregular macrocrystal structure characterized by a diffraction peak in a {111} diffraction plane having at least one of the following structural properties: (i) a measured full width half maximum (FWIIM) of the peak being at least 0.24 degrees of 2?; and (ii) a net full width half maximum (net FWHM) of the peak being at least 0.14 degrees of 2?.

Abstract: A biocompatible putty formulation suitable for insertion within chronic and acute wounds of humans and animals, the formulation containing a topical antibiotic, a biocompatible humectant, a biocompatible viscosity-building agent, and at least 5% water, by weight, the humectant and the viscosity-building agent intimately mixed within the formulation, the formulation adapted whereby the formulation remains a solid over the entire temperature range of 20° C. to 35° C.

Abstract: A topical formulation for application to exposed body tissue, the formulation comprising a silver(II) oxide and zinc oxide, intimately dispersed within a carrier medium.